Literature DB >> 16364308

Mitochondrial targeting of growth suppressor protein DLC2 through the START domain.

David Chi-Heng Ng1, Shing-Fai Chan, Kin Hang Kok, Judy Wai Ping Yam, Yick-Pang Ching, Irene Oi-Lin Ng, Dong-Yan Jin.   

Abstract

Deleted in liver cancer 2 (DLC2) is a candidate tumor suppressor frequently found to be deleted in hepatocellular carcinoma. In this study, we determined the subcellular localization of DLC2. Co-localization and biochemical fractionation studies revealed that DLC2 localized to mitochondria. In addition, the DLC2-containing cytoplasmic speckles were in proximity to lipid droplets. A DLC2 mutant containing the steroidogenic acute regulatory protein-related lipid transfer (START) domain only showed a localization pattern identical to that of DLC2. Taken together, we have provided the first evidence for mitochondrial localization of DLC2 through the START domain. These findings might have implications in liver physiology and carcinogenesis.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16364308     DOI： 10.1016/j.febslet.2005.11.073

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  13 in total

1.  Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.

Authors:  Iryna A Khasabova; Sergey Khasabov; Justin Paz; Catherine Harding-Rose; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2012-05-16       Impact factor: 6.167

2.  Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein.

Authors:  Ching-Ping Chan; Kam-Leung Siu; King-Tung Chin; Kwok-Yung Yuen; Bojian Zheng; Dong-Yan Jin
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Expression of deleted in liver cancer 2 in colorectal cancer and its correlation with clinicopathological parameters.

Authors:  Kai Gao; Xiaorong Li; Gui Hu; Kaiyan Yang; Buning Tian; Yi Zhang
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

4.  Deleted in liver cancer 2 (DLC2) was dispensable for development and its deficiency did not aggravate hepatocarcinogenesis.

Authors:  Tai On Yau; Thomas Ho Yin Leung; Sandra Lam; Oi Fung Cheung; Edmund Kwok Kwan Tung; Pek Lan Khong; Amy Lam; Sookja Chung; Irene Oi Lin Ng
Journal:  PLoS One       Date:  2009-08-10       Impact factor: 3.240

5.  StARD13(Dlc-2) RhoGap mediates ceramide activation of phosphatidylglycerolphosphate synthase and drug response in Chinese hamster ovary cells.

Authors:  Grant M Hatch; Yuan Gu; Fred Y Xu; Jeannick Cizeau; Shannon Neumann; Ji-Seon Park; Shauna Loewen; Michael R A Mowat
Journal:  Mol Biol Cell       Date:  2007-12-27       Impact factor: 4.138

6.  A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide.

Authors:  David Barras; Nadja Chevalier; Vincent Zoete; Rosemary Dempsey; Karine Lapouge; Monilola A Olayioye; Olivier Michielin; Christian Widmann
Journal:  J Biol Chem       Date:  2014-07-09       Impact factor: 5.157

7.  Deleted in liver cancer protein family in human malignancies (Review).

Authors:  D Lukasik; E Wilczek; A Wasiutynski; B Gornicka
Journal:  Oncol Lett       Date:  2011-07-05       Impact factor: 2.967

Review 8.  Deleted in liver cancer-1 (DLC-1): a tumor suppressor not just for liver.

Authors:  Yi-Chun Liao; Su Hao Lo
Journal:  Int J Biochem Cell Biol       Date:  2007-04-20       Impact factor: 5.085

9.  The NMR structure of the murine DLC2 SAM domain reveals a variant fold that is similar to a four-helix bundle.

Authors:  Jamie J Kwan; Logan W Donaldson
Journal:  BMC Struct Biol       Date:  2007-05-22

10.  Underexpression of deleted in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor prognosis in hepatocellular carcinoma.

Authors:  Li Xiaorong; Wu Wei; Qian Liyuan; Yang Kaiyan
Journal:  BMC Cancer       Date:  2008-07-23       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.